Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of rPA in Acute Pulmonary Embolism
NCT04110275Phase 2Unknown
- Sponsor
- China Resources Angde Biopharmaceutical
- Start
- Oct 2019
- Primary completion
- May 2021
- Modality
- rProtein (Recombinant Protein), Biologic
01
Overview
A Phase 2 trial of Ruitongli in pulmonary embolism (PE), sponsored by China Resources Angde Biopharmaceutical. Status: unknown.
02
Drugs
Ruitongli
03
Conditions
pulmonary embolism (PE)
Beyond the preview
Go deeper on NCT04110275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04110275.